Cardiogenic Shock: Culprit Vessel Paradox?

By, Rajesh Dave, MD Despite innovation in stents, balloons, adjunctive devices, etc. the mortality in cardiogenic shock remains around 50% in the best-case scenario – outside of western hemisphere it…

Update: ODYSSEY Outcomes

Update on ODYSSEY Outcomes – by Dr. Rajesh Dave, MD, FSCAI, FACC ODYSSEY Outcomes, the second of the cardiovascular outcomes studies with a PCSK9 inhibitor, this time in an acute